

Supplementary Online Material

Dolph M, Tremblay G, Gilligan AM, Leong H. Network meta-analysis of once weekly selinexor-bortezomib-dexamethasone in previously treated multiple myeloma. *JHEOR*. 2021;8(2):26-35.

[doi:10.36469/jheor.2021.27080](https://doi.org/10.36469/jheor.2021.27080)

Table S1. Study Characteristics (2L Population)

Table S2. Study Characteristics (3L+ Population)

Table S3. 2L PFS Ranking Probability Results

Table S4. 2L OS Ranking Probability Results

Table S5. 2L ORR Ranking Probability Results

Table S6. 3L+ PFS Ranking Probability Results

Table S7. 3L+ OS Ranking Probability Results

Table S8. 3L+ ORR Ranking Probability Results

This supplementary material has been provided by the authors to give readers additional information about their work.



Table S1. Study Characteristics (2L Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Dimopoulos_ASCO_2020 (abstract)	BOSTON (NCT03110562)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	SEL+BOR+DEX	SEL: 100 mg BOR: 1.3 mg/m ² DEX: 20 mg	13.2	6.9	195	66	59%
				BOR+DEX	BOR: 1.3 mg/m ² DEX: 20 mg	16.5	7.4	207	67	56%
Dimopoulos_Haematologica_2018 Jonathan_ASH_2019 (abstract)	POLLUX (NCT02076009)	P3, RCT, open-label, multicenter	previously treated MM with at least 1 prior LOT	DAR+LEN+DEX	LEN: 25 mg; DEX: 40 mg; DAR: 16mg/kg	51.3	34.3	286	65	NR
				LEN+DEX	LEN: 25 mg; DEX: 40 mg	51.3	16.0	283	65	NR
Mateos_Haematologica_2017	TOURMALINE-MM1 (NCT01564537)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	IXA+LEN+DEX	IXA: 4 mg; LEN: 25mg; DEX: 40mg (LEN: 10mg if creatinine clearance <60mL/min)	14.8	NR	360	66	58%*
				LEN+DEX	PBO: 4 mg; LEN: 25mg; DEX: 40mg (LEN: 10mg if creatinine clearance <60mL/min)	14.6	NR	362	66	56%*
Spencer_Haematologica_2018 Katja_ASH_2019 (abstract)	CASTOR (NCT02136134)	P3, RCT, open-label, multicenter	previously treated MM with at least 1 prior LOT	DAR+BOR+DEX	BOR: 1.3mg/m ² ;DEX: 20mg; DAR: 16mg/kg	47.0	13.4	251	64	NR
				BOR+DEX	BOR: 1.3mg/m ² ; DEX: 20mg	47.0	5.2	247	64	NR
Kropff_AH_2017	NCT00813150	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	BOR+DEX	BOR: 1.3mg/m ² ; DEX: 20mg	24.00	3.6	46	68	54%
				CYC+BOR+DEX	BOR:1.3mg/m ² ; DEX=20mg;CYC=50mg	24.00	3.6	47	71	55%
Jakubowiak_Blood_2016	NCT01478048	P2, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	ELO+BOR+DEX	ELO: 10mg/kg; BOR: 1.3mg/m ² ;DEX: 16mg and 20mg	15.9	NR	77	65	55%
				BOR+DEX	BOR: 1.3mg/m ² ; DEX: 20mg	11.7	NR	75	65	49%
Richardson_LO_2019	OPTIMISMM (NCT01734928)	P2, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	POM+BOR+DEX	POM: 4 mg; BOR: 1.3 mg/m ² ;DEX: 20 mg	15.9	8.8	281	67	55%
				BOR+DEX	BOR: 1.3 mg/m ² ; DEX: 20 mg	15.9	4.9	278	68	53%
Moreau_Leukemia_2017 (Subgroup 1 prior LOT))	ENDEAVOR (NCT01568866)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	CAR+DEX	CAR: 20mg/m ² days 1-2 (cycle 1),56mg/m ² thereafter; DEX: 20mg	NR	9.6	232	60	NR
				BOR+DEX	BOR: 1.3mg/m ² ; DEX: 20mg	NR	7.1	232	64	NR

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

** Weber (207) and Dimopoulos (2007) were both majority 3L+ populations, but were required in the 2L network to link LEN+DEX with DEX.

Table S1. Study Characteristics (2L Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Iida_CS_2018	JCOG0904, UMIN000003135	P2, RCT, open-label, multicenter	Japanese adults ($\geq 20 < 80$) with MM who received at least 1 prior LOT	BOR+DEX	BOR: 1.3mg/m ² ; DEX: 20mg	34.3	NR	22	65	45%
				THAL+DEX	THAL: 200mg/d; DEX: 20mg	34.3	NR	22	67	59%
Yong_EHA_2018 (poster)	MUK Five	P2, RCT, open-label, multicenter	previously treated MM with 1 prior LOT	CAR+CYC+DEX	CAR: 20 & 36 mg/m ² ; CYC: 500mg; DEX: 40 mg	14.0	5.5	141	NR	NR
				BOR+CYC+DEX	BOR: 1.3 mg/m ² ; CYC: 500mg; DEX: 40 mg	14.0	5.5	99	NR	NR
Montefusco_BJH_2020	EUDRACT 2010-021557-40	P3, RCT, open-label, multicenter	MM at first relapse	LEN+CYC+DEX	LEN: 15 mg; CYC: 500 mg/m ² ; DEX: 20 mg	32.0	8.3*	79	64	55.7%
				BOR+CYC+DEX	BOR: 1.3mg/m ² ; CYC: 500 mg/m ² ; DEX: 20 mg	34.0	10.4*	76	65	36.8%
White_Cancer_2013	AMBER (NCT00473590)	P2, RCT, open label, multicenter	1-3 prior therapies	BEV+BOR	BOR: 1.3 mg/m ² ; BEV: 15 mg/kg	13.3	4.2	49	65	59%
				BOR	BOR: 1.3 mg/m ²	13.3	NR	53	65	57%
Richardson_NEJM_2005	APEX	P3, RCT, open label, multicenter	1-3 prior therapies	BOR	BOR: 1.3 mg/m ²	8.0	NR	333	62	56%
				DEX	DEX: 40 mg	8.0	NR	336	61	60%
Weber_NEJM_2007**	MM-009 (NCT00056160)	P3, RCT, double blind, multicenter	≥ 1 prior therapy	LEN+DEX	LEN: 25 mg; DEX: 40mg	26.2	10.2	177	64	60%
				PBO+DEX	DEX: 40mg	12.9	NR	176	62	59%
Dimopoulos_NEJM_2007**	MM-010 (NCT00424047)	P3, RCT, double blind, multicenter	≥ 1 prior therapy	LEN+DEX	LEN: 25 mg; DEX: 40mg	16.4	10.2	176	63	59%
				PBO+DEX	DEX: 40mg	16.4	NR	175	64	58%
Orlowski_AJH_2015	NR	P2, RCT, double blind, multicenter	1-3 prior therapies	SIL+BOR	SIL: 6 mg/kg; BOR: 1.3 mg/m ²	24.5	4.7	142	64	51%
				BOR	BOR: 1.3 mg/m ²	24.5	4.7	144	61	59%
Dimopoulos_LO_2013	VANTAGE 088 (NCT00773747)	P3, RCT, double blind, multicenter	1-3 prior therapies	VOR+BOR	BOR: 1.3 mg/m ² ; VOR: 400 mg	14.2	NR	317	61	60%
				BOR	BOR: 1.3 mg/m ²	NR	NR	320	63	58%
Siegel_JCO_2018	ASPIRE (NCT01080391)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	CAR+LEN+DEX	CAR: 20 & 27 mg/m ² ; LEN: 25 mg; DEX: 40 mg	67.1	20.1*	396	63*	NR
				LEN+DEX	LEN: 25 mg; DEX: 40 mg	67.1	13.1*	396	65*	NR

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

** Weber (2007) and Dimopoulos (2007) were both majority 3L+ populations, but were required in the 2L network to link LEN+DEX with DEX.

Table S1. Study Characteristics (2L Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
San-Miguel_Lancet_2016	PANORAMA 1 (NCT01023308)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	PAN+BOR+DEX	PAN: 20 mg; BOR: 1.3 mg/m ² ; DEX: 20 mg	NR	NR	387	63	52%
				Vd	BOR: 1.3 mg/m ² ; DEX: 20 mg	NR	NR	381	63	54%
Orlowski_CLML_2019	ENDEAVOR (NCT01568866)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	CAR+DEX	CAR: 20mg/m ² days 1-2 (cycle 1), 56mg/m ² thereafter; DEX: 20mg	44.3	11.1	464	65	NR
				Vd	BOR: 1.3mg/m ² ; DEX: 20mg	43.7	6.2	465	65	NR
Chiou_CI_2007	NR	P2, RCT, open label, multicenter,	1 prior therapies	THAL+InfA	THAL: 200 mg/day up to 800 mg/day; INF: 3 MIU/m ² subcutaneous injection thrice weekly,	NR	NR	16	64	81%
				THAL	THAL: 200 mg/day up to 800 mg/day	NR	NR	12	62	92%
Richardson_Blood_2016 (≥2 prior LOT including BTZ and an IMiD)	PANORAMA 1 (NCT01023308)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	PAN+BOR+DEX	PAN 20 mg + BOR 1.3 mg/m ² + DEX 20 mg	NR	6.4	73	61	56%
				Vd	PBO + BOR 1.3 mg/m ² + DEX 20 mg	NR	4.9	74	61	45%
Moreau_ASH_2019 (abstract)	BELLINI (NCT02755597)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	VEN+BOR+DEX	VEN: 800 mg; BOR: 1.3 mg/m ² ; DEX: 20 mg	22.7	NR	194	66	NR
				PBO+BOR+DEX	BOR: 1.3 mg/m ² ; DEX: 20 mg	22.7	NR	97	66	NR
Hus_AH_2011	NR	RCT, multicenter	≥1 prior therapy	LOV+THAL+DEX	LOV: 2mg/kg / 0.5 mg/kg ; THAL: 100 mg ; DEX: 20 mg	NR	NR	49	59	49%
				THAL+DEX	THAL: 100 mg; DEX: 20 mg	NR	NR	42	62	48%
Dimopoulos_Haematologica_2015	patients with one prior line in MMY-2045 (NCT00908232), APEX (NCT00048230), and DOX-IL-MMY-3001 (NCT00103506)	Retrospective matched-pairs analysis	1 prior therapy	BOR+DEX	median cumulative doses of bortezomib was 27.02 mg/m ² (range 1.3- 41.7 mg/m ²); median cumulative dose of dexamethasone of 880 mg (range 20-1280 mg)	26.1	4.5	109	62	NR
				BOR	median cumulative doses of bortezomib was 28.60 mg/m ² (range 2.4-59.1 mg/m ²)	18.4	4.1	109	64	NR

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

** Weber (207) and Dimopoulos (2007) were both majority 3L+ populations, but were required in the 2L network to link LEN+DEX with DEX.

Table S1. Study Characteristics (2L Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Dimopoulos_Cancer_2018	ELOQUENT-2 (NCT01239797)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	ELO+LEN+DEX	NR	46	NR	319	67	60%*
				LEN+DEX	NR		NR			316
Usmani_Blood_2019 (abstract)	CANDOR (NCT03158688)	P3, RCT, open-label, multicenter	previously treated MM with 1-3 prior LOT	DAR+CAR+DEX	DAR: 8 mg/kg then 16 mg/kg CAR: 20 mg/m ² on cycle 1 days 1 and 2 and 56 mg/m ² beginning on cycle 1 day 8 and thereafter DEX: 40 mg	17	16.14144737	312	64	NR
CAR+DEX				CAR: 20 mg/m ² on cycle 1 days 1 and 2 and 56 mg/ m ² beginning on cycle 1 day 8 and thereafter DEX: 40 mg	9.279605263		154			
Weisel_EHA_2020 (abstract)										

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

** Weber (207) and Dimopoulos (2007) were both majority 3L+ populations, but were required in the 2L network to link LEN+DEX with DEX.

Table S2. Study Characteristics (3L+ Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Dimopoulos_ASCO_2020 (abstract)	BOSTON (NCT03110562)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	SEL+BOR+DEX	SEL: 100 mg BOR: 1.3 mg/m ² DEX: 20 mg	13.2	6.9	195	66	59%
				BOR+DEX	BOR: 1.3 mg/m ² DEX: 20 mg	16.5	7.4	207	67	56%
Dimopoulos_Cancer_2018	ELOQUENT-2 (NCT01239797)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	ELO+LEN+DEX	NR	46	NR	319	67	NR
				LEN+DEX	NR	46	NR	316	67	NR
Hou_JHO_2017	TOURMALINE-MM1 (NCT01564537)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	IXA+LEN+DEX	IXA: 4 mg; LEN: 25mg; DEX: 40mg (LEN: 10mg if creatinine clearance <60mL/min)	20	9.1	57	61	41%
				LEN+DEX	PBO: 4 mg; LEN: 25mg; DEX: 40mg (LEN: 10mg if creatinine clearance <60mL/min)	20	6	58	62	38%
Bernal-Mizrachi_ASH_2019 (abstract) (NFKB2 FISH [+ subgroup])	NCT02765854	P2, RCT, open-label, multicenter	Patients with early relapsed multiple myeloma with NFKB2 FISH [+], who received <4 prior LOT	LEN+IXA+DEX	LEN: 25 mg; IXA: 4 mg; DEX: 40 mg	NR	NR	12	NR	NR
				IXA+DEX	IXA: 4 mg; DEX: 40 mg	NR	NR	13	NR	NR
Raje_BJH_2017	NCT01602224	P2, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	TAB+BOR+DEX	TAB: 100 mg; BOR: 1.3 mg/m ² ; DEX: 20 mg	NR	NR	74	64	30%
				TAB+BOR+DEX	TAB: 300 mg; BOR: 1.3 mg/m ² ; DEX: 20 mg	NR	NR	74	67	37%
				BOR+DEX	BOR: 1.3 mg/m ² ; DEX: 20 mg	NR	NR	72	67	40%
Moreau_Leukemia_2017 (Subgroup ≥2 prior LOT)	ENDEAVOR (NCT01568866)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	CAR+DEX	CAR: 20mg/m ² days 1-2 (cycle 1), 56mg/m ² thereafter; DEX: 20mg	NR	8.8	232	64	NR
				BOR+DEX	BOR: 1.3mg/m ² ; DEX: 20mg	NR	6.7	233	66	NR

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

Table S2. Study Characteristics (3L+ Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Yong_Blood_2017 (slides)	MUK Five	P2, RCT, open-label, multicenter	previously treated MM with 1 prior LOT	CAR+CYC+DEX	CAR: 20 & 36 mg/m ² ; CYC: 500mg; DEX: 40 mg	NR	NR	201	67	58%
				BOR+CYC+DEX	BOR: 1.3 mg/m ² ; CYC: 500mg; DEX: 40 mg	NR	NR	99	69	65%
Attal_Lancet_2019	ICARIA-MM (NCT02990338)	P3, RCT, open-label, multicenter	previously treated MM with at least 2 prior LOT	ISA+POM+DEX	ISA: 10mg/kg; POM: 4mg; DEX: 40mg	11.6	9.4	154	68	58%
Richardson_ASCO_2019 (abstract)	POM+DEX			POM: 4mg; DEX: 40mg	11.6	5.5	153	66	46%	
Bringhen_CLML_2019 (abstract) (Subgroup >3 prior LOT)	ICARIA-MM (NCT02990338)	P3, RCT, open-label, multicenter	previously treated MM with at least 2 prior LOT	ISA+POM+DEX	ISA: 10mg/kg; POM: 4mg; DEX: 40mg	11.6	NR	52	NR	NR
				POM+DEX	POM: 4mg; DEX: 40mg	11.6	NR	52	NR	NR
Mateos_LH_2019	KEYNOTE-183 (NCT02576977)	P3, RCT, open-label, multicenter	previously treated MM with at least 2 prior LOT	PEM+POM+DEX	PEM: 200 mg; POM: 4 mg; DEX: 40 mg	NR	4.1	126	66	62%
				POM+DEX	POM: 4 mg; DEX: 40mg	NR	4.2	125	64	63%
Dimopoulos_NEJM_2018	ELOQUENT-3 (NCT02654132)	P2, RCT, open-label, multicenter	previously treated MM with at least 2 prior LOT	ELO+POM+DEX	ELO: 10 mg/kg; POM: 4 mg; DEX: 40 mg (20 mg if >75 years)	NR	NR	60	69	53%
Dimopoulos_CLML_2019 (abstract)	POM+DEX			POM: 4 mg; DEX: 40 mg (20 mg if >75 years)	NR	NR	57	66	61%	
NCT01794039	NCT01794039	P2, RCT, open-label, single center	Patients ≥ 18 years old with relapsed myeloma that previously became refractory to lenalidomide	LEN+DEX	NR	NR	NR	5	67	60%
				POM+DEX	NR	NR	NR	4	69	75%
Richardson_Blood_2007	APEX	P3, RCT, open label, multicenter	1-3 prior therapies	BOR	BOR: 1.3 mg/m ²	22	4.1	333	62	56%
				DEX	DEX: 40 mg	22	4.1	336	61	60%
Orlowski_JCO_2007	NCT00103506	P3, RCT, open label, multicenter	≥1 prior therapy	PLD+BOR	PLD: 30 mg/m ² ; BOR: 1.3 mg/m ²	NR	3.5	322	61	58%
				BOR	BOR: 1.3 mg/m ²	NR	3.5	324	62	54%
Richardson_Blood_2014	MM-002 (NCT00833833)	P2, RCT, open label, multicenter	≥1 prior therapy	POM+LoDEX	POM: 4 mg/day ; DEX: 40 mg/week	14.2	NR	113	63	54%
				POM	POM: 4 mg/day	14.2	NR	108	63	54%

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

Table S2. Study Characteristics (3L+ Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Dimopoulos_Haematologica_2015	MM-003 (NCT01311687)	P3, RCT, open label, multicenter, subgroup analysis	≥2 prior therapies	POM+LoDEX	POM: 4 mg/day; DEX: 40 mg/day	15.4	3.5	302	64	NR
				HiDEX	DEX: 40 mg/day	15.4	NR	153	65	NR
Offidani_HJ_2004	NR	P2, RCT, open label, multicenter,	≥1 prior therapies	THAL+MEL	THAL: 100 mg/day - 600 mg/day; MEL: 0.20 mg/kg/day	NR	NR	23	69	37%
				THAL	THAL: 100 mg/day- up to 600 mg/day	NR	NR	23	74	43%
Hjorth_EJH_2012	NCT00602511	P3, RCT, open label, multicenter	≥1 prior therapies	THAL+DEX	THAL: 50 mg; DEX: 40 mg	NR	5.1	67	71	42%
				BOR+DEX	BOR: 1.3 mg/m; DEX: 20 mg	NR	3.5	64	71	64%
Dimopoulos_Haematologica_2015	patients with one prior line in MMY-2045 (NCT00908232), APEX (NCT00048230), and DOXIL-MMY-3001 (NCT00103506)	Retrospective matched-pairs analysis	1 prior therapy	BOR+DEX	median cumulative doses of bortezomib was 27.02 mg/m ² (range 1.3- 41.7 mg/m ²); median cumulative dose of dexamethasone of 880 mg (range 20-1280 mg)	26.1	4.5	109	62	NR
				BOR	median cumulative doses of bortezomib was 28.60 mg/m ² (range 2.4-59.1 mg/m ²)	18.4	4.1	109	64	NR
Baz_Blood_2016	NCT01432600	P2, RCT, open-label, multicenter	previously treated MM with at least 2 prior LOT	POM+DEX	POM: 4 mg DEX: 40 mg	NR	NR	36	64	0.64
				CYC+POM+DEX	CYC: 400 mg POM: 4 mg DEX: 40 mg					
Bringhen_CLML_2019 (abstract) (Subgroup 2-3 prior LOT)	ICARIA-MM (NCT02990338)	P3, RCT, open-label, multicenter	previously treated MM with at least 2 prior LOT	ISA+POM+DEX	ISA: 10mg/kg POM: 4mg DEX: 40mg	11.6	NR	102	NR	NR
				POM+DEX	POM: 4mg DEX: 40mg					

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

Table S2. Study Characteristics (3L+ Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)			
Croft_ASH_2018 (abstract)	Muk seven (NCT02406222)	P2, RCT, open-label, multicenter	previously treated MM with at least 2 prior LOT	CYC+POM+DEX	CYC: 500 mg POM: 4 mg DEX: 40 mg (20 mg if >75 years)	NR	NR	51	NR	NR			
				POM+DEX	POM: 4 mg DEX: 40 mg (20 mg if >75 years)		NR						
Dimopoulos_Haematologica_2018 Jonathan_ASH_2019 (abstract)	POLLUX (NCT02076009)	P3, RCT, open-label, multicenter	previously treated MM with at least 1 prior LOT	DAR+LEN+DEX	LEN: 25 mg DEX: 40 mg DAR: 16mg/kg	51.3	34.3	286	65	NR			
				LEN+DEX	LEN: 25 mg DEX: 40 mg		16				283	65	NR
Dimopoulos_LO_2013	VANTAGE 088 (NCT00773747)	P3, RCT, double blind, multicenter	1-3 prior therapies	VOR+BOR	BOR: 1.3 mg/m ² VOR: 400 mg	14.2	NR	317	60.9	60%			
				PBO+BOR	BOR: 1.3 mg/m ²		NR				NR	320	62.7
Dimopoulos_NEJM_2007	MM-010 (NCT00424047)	P3, RCT, double blind, multicenter	≥1 prior therapy	LEN+DEX	LEN: 25 mg DEX: 40mg	16.4	10.15384615	176	63	59%			
				PBO+DEX	DEX: 40mg		NR				175	64	58%
Hajek_Leukemia_2017	FOCUS (NCT01302392)	P3, RCT, open-label, multicenter	previously treated MM with at least 3 prior LOT	CAR	CAR: 20 mg	27.8	16.3	157	63	52%			
				COR+/-CYC	COR (Prednisone: 30 mg, DEX: 6 mg) CYC: 50 mg		29.8				10.7	158	66
Huang_EHA_2020 (abstract)	MMY3009 (LEPUS)	P3, RCT, multicenter	previously treated MM with at least 1 prior LOT	DAR+BOR+DEX	DAR: 16 mg/kg BOR: 1.3 mg/m ² DEX: 20 mg	8.2	NR	141	61	NR			
				BOR+DEX	BOR: 1.3 mg/m ² DEX: 20 mg		NR				70	61	NR
Jakubowiak_Blood_2016	NCT01478048	P2, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	ELO+BOR+DEX	ELO: 10mg/kg BOR: 1.3mg/m ² DEX: 16mg and 20mg	15.9	NR	77	65	55%			
				BOR+DEX	BOR: 1.3mg/m ² DEX: 20mg		11.7				NR	75	65
Kropff_Haematologica_2012	OPTIMUM (NCT00452569)	P3, RCT, open label, multicenter	1-3 prior therapies	THAL 100	THAL: 100 mg/day	NR	6.447368421	121	64	45%			
				THAL 200	THAL: 200 mg/day		6.447368421				122	63	46%
				THAL 400	THAL: 400 mg/day		6.447368421				130	65	59%
				DEX	DEX: 40 mg/day		5.526315789				126	63	45%

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

Table S2. Study Characteristics (3L+ Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Kumar_EHA_2020 (abstract), Moreau_ASH_2019 (abstract)	BELLINI (NCT02755597)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	VEN+BOR+DEX	VEN: 800 mg BOR: 1.3 mg/m ² DEX: 20 mg	28.6	NR	194	66	NR
				PBO+BOR+DEX	BOR: 1.3 mg/m ² DEX: 20 mg		NR	97	66	NR
Mateos_Haematologica_2017	TOURMALINE-MM1 (NCT01564537)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	IXA+LEN+DEX	IXA: 4 mg LEN: 25mg DEX: 40mg (LEN: 10mg if creatinine clearance <60mL/min)	14.8	NR	360	NR	NR
				PBO+LEN+DEX	PBO: 4 mg LEN: 25mg DEX: 40mg (LEN: 10mg if creatinine clearance <60mL/min)	14.6		362	NR	NR
Orlowski_CLML_2019	ENDEAVOR (NCT01568866)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	CAR+DEX	CAR: 20mg/m ² days 1-2 (cycle 1), 56mg/ m ² thereafter DEX: 20mg	44.3	11.1	464	65	NR
				BOR+DEX	BOR: 1.3mg/m ² DEX: 20mg	43.7	6.2	465	65	NR
Richardson_Blood_2016 (≥2 prior LOT including BTZ and an IMiD)	PANORAMA 1 (NCT01023308)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	PAN+BOR+DEX	PAN 20 mg + BOR 1.3 mg/m ² + DEX 20 mg	NR	6.4	73	61	56%
				PBO+BOR+DEX	PBO + BOR 1.3 mg/m ² + DEX 20 mg	NR	4.9	74	61	45%
Richardson_LO_2019	OPTIMISMM (NCT01734928)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	POM+BOR+DEX	POM: 4 mg BOR: 1.3 mg/m ² DEX: 20 mg	15.9	8.8	281	67	55%
				BOR+DEX	BOR: 1.3 mg/m ² DEX: 20 mg		4.9	278	68	53%
San-Miguel_Lancet_2016	PANORAMA 1 (NCT01023308)	P3, RCT, double blind, multicenter	previously treated MM with 1 to 3 prior LOT	PAN+BOR+DEX	PAN: 20 mg BOR: 1.3 mg/m ² DEX: 20 mg	NR	NR	387	63	52%
				PBO+BOR+DEX	BOR: 1.3 mg/m ² DEX: 20 mg	NR	NR	381	63	54%

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

Table S2. Study Characteristics (3L+ Population)

Short Reference	Study Acronym	Study Design	Study Population	Interventions Acronym	Tx Dosage Included (mg)	Follow-Up (median months)	Duration of Treatment (median months)	N	Age (median)	Male (%)
Siegel_JCO_2018	ASPIRE (NCT01080391)	P3, RCT, open-label, multicenter	previously treated MM with 1 to 3 prior LOT	CAR+LEN+DEX	CAR: 20 & 27 mg/m ² LEN: 25 mg DEX: 40 mg	67.1	20.1*	396	63*	NR
				LEN+DEX	LEN: 25 mg DEX: 40 mg		13.1*			
Spencer_Haematologica_2018 Katja_ASH_2019 (abstract)	CASTOR (NCT02136134)	P3, RCT, open-label, multicenter	previously treated MM with at least 1 prior LOT	DAR+BOR+DEX	BOR: 1.3mg/m ² DEX: 20mg DAR: 16mg/kg	47.0	13.4	251	64	NR
				BOR+DEX	BOR: 1.3mg/m ² DEX: 20mg		5.2			
Usmani_Blood_2019 (abstract) Weisel_EHA_2020 (abstract)	CANDOR (NCT03158688)	P3, RCT, open-label, multicenter	previously treated MM with 1-3 prior LOT	DAR+CAR+DEX	DAR: 8 mg/kg then 16 mg/kg CAR: 20 mg/m ² on cycle 1 days 1 and 2 and 56 mg/m ² beginning on cycle 1 day 8 and thereafter DEX: 40 mg	17	16.1	312	64	NR
				CAR+DEX	CAR: 20 mg/m ² on cycle 1 days 1 and 2 and 56 mg/m ² beginning on cycle 1 day 8 and thereafter DEX: 40 mg		9.3			
Verkleij_Blood_2019 (abstract)	NCT03184194	P2, RCT, multicenter	previously treated MM with at least 2 prior LOT	NIV+DAR+low dose CYC	DAR: 16 mg/kg NIV: 240 mg in cycles 1-6 and 480 mg thereafter Low-dose CYC: 50 mg	8.6	NR	20	64	45%
				NIV+DAR	DAR: 16 mg/kg NIV: 240 mg in cycles 1-6 and 480 mg thereafter		NR			
Weber_NEJM_2007	MM-009 (NCT00056160)	P3, RCT, double blind, multicenter	≥1 prior therapy	LEN+DEX	LEN: 25 mg DEX: 40mg	26.2	10.15	177	64	60%
				PBO+DEX	DEX: 40mg		12.9			

* Numbers are from the same trial but old references, as the updated reference did not report those baseline values.

Table S3. 2L PFS Ranking Probability Results

Probability of Rank (%)	Treatment																				
	Vd	XVd	BOR	Rd	KRd	ERd	DRd	IRd	RCyd	DVd	EVd	PVd	VCyd	VOR+ BOR	BEV+ BOR	SIL+ BOR	DKd	Kd	KCyd	DEX	Td
Rank 1	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	83.1	0.0	0.0	0.0	0.0	0.0	0.0	13.6	0.0	0.0	0.0	0.0
Rank 2	0.0	0.6	0.0	0.0	0.1	0.0	19.2	0.0	0.0	15.7	0.6	3.2	0.0	0.0	0.0	0.0	56.6	3.8	0.0	0.0	0.0
Rank 3	0.0	2.6	0.0	0.0	2.1	0.6	25.4	0.2	0.0	1.1	2.6	10.6	0.0	0.0	0.1	0.0	17.6	36.9	0.0	0.0	0.0
Rank 4	0.0	6.9	0.0	0.0	5.1	2.1	18.3	0.8	0.1	0.1	6.4	20.6	0.0	0.0	0.2	0.0	5.9	33.4	0.0	0.0	0.0
Rank 5	0.0	14.4	0.0	0.1	8.3	4.3	14.3	2.0	0.2	0.0	12.7	25.0	0.0	0.1	0.5	0.0	2.9	14.9	0.2	0.0	0.1
Rank 6	0.1	20.7	0.0	0.3	12.2	7.5	10.1	3.8	0.5	0.0	18.4	16.5	0.0	0.4	1.0	0.0	1.6	6.0	0.8	0.0	0.1
Rank 7	1.9	18.5	0.0	1.0	15.5	11.4	6.8	6.4	1.3	0.0	18.5	9.9	0.2	1.1	1.9	0.0	0.8	2.7	1.9	0.0	0.4
Rank 8	10.4	10.2	0.0	2.6	18.6	15.6	1.5	10.1	2.4	0.0	10.6	5.4	0.6	2.5	3.2	0.1	0.4	1.3	3.7	0.0	0.8
Rank 9	10.4	7.8	0.0	5.7	13.3	17.0	0.5	13.1	3.2	0.0	8.2	3.7	1.6	4.2	4.0	0.3	0.2	0.6	5.1	0.0	1.3
Rank 10	11.6	6.3	0.0	10.6	8.4	13.0	0.3	14.4	3.8	0.0	6.7	2.4	3.0	6.3	5.0	0.7	0.1	0.3	5.6	0.0	1.5
Average rank	11.64	7.24	18.21	12.76	8.07	9.29	3.93	10.84	15.49	1.18	7.54	5.46	16.05	13.49	14.37	16.44	2.42	4.01	14.12	20.76	17.69
Probability of being in top 5 (%)	0.0	24.5	0.0	0.1	15.7	7.1	80.6	3.1	0.3	100.0	22.4	59.4	0.0	0.2	0.8	0.0	96.6	89.0	0.3	0.0	0.1

Abbreviations: Vd, bortezomib + dexamethasone; XVd, selinexor + bortezomib + dexamethasone; BOR, bortezomib; Rd, lenalidomide + dexamethasone; KRd, carfilzomib + lenalidomide + dexamethasone; ERd, elotuzumab + lenalidomide + dexamethasone; DRd, daratumumab + lenalidomide + dexamethasone; IRd, ixazomib + lenalidomide + dexamethasone; RCyd, lenalidomide + cyclophosphamide + dexamethasone; DVd, daratumumab + bortezomib + dexamethasone; EVd, elotuzumab + bortezomib + dexamethasone; PVd, pomalidomide + bortezomib + dexamethasone; VCyd, bortezomib + cyclophosphamide + dexamethasone; VOR+BOR, vorinostat + bortezomib; BEV+BOR, bevacizumab + bortezomib; SIL+BOR, siltuximab + bortezomib; DKd, daratumab + carfilzomib + dexamethasone; Kd, carfilzomib + dexamethasone; KCyd, carfilzomib + cyclophosphamide + dexamethasone; DEX, dexamethasone; Td, thalidomide + dexamethasone.

Table S4. 2L OS Ranking Probability Results

Probability of Rank (%)	Treatment															
	Vd	XVd	BOR	Rd	KRd	ERd	IRd	EVd	VCyd	BEV+ BOR	SIL+ BOR	Kd	DEX	Td	FVd	
Rank 1	0.0	11.4	0.1	0.0	0.9	0.4	26.6	28.1	1.4	26.6	0.0	3.2	0.0	0.7	0.5	
Rank 2	0.0	17.7	1.0	0.1	4.5	1.9	15.3	23.4	2.9	17.7	0.1	11.4	0.0	1.4	2.6	
Rank 3	0.3	16.8	2.8	0.7	7.1	3.6	9.7	15.3	4.0	11.0	0.4	19.3	0.0	1.8	7.2	
Rank 4	2.4	13.1	5.2	2.3	7.3	4.9	6.9	9.3	4.9	7.8	0.7	20.3	0.0	2.2	12.8	
Rank 5	8.6	9.6	7.3	3.6	6.9	5.2	5.6	6.4	5.5	6.2	1.3	15.2	0.0	2.5	16.0	
Rank 6	15.8	7.5	9.6	4.2	6.8	5.3	4.9	4.8	6.0	5.4	2.0	10.0	0.1	2.8	14.8	
Rank 7	17.6	6.1	12.7	4.5	6.9	5.5	4.9	3.6	7.2	5.2	2.9	7.1	0.1	3.8	12.0	
Rank 8	14.3	4.8	16.5	5.1	8.1	6.2	5.3	2.7	7.9	4.7	4.8	5.2	0.2	4.7	9.5	
Rank 9	11.2	3.8	16.4	6.0	10.2	7.7	5.1	2.0	8.2	3.7	8.4	3.7	0.3	5.5	7.7	
Rank 10	9.9	2.9	11.8	8.6	12.3	10.2	4.6	1.5	7.8	2.9	11.9	2.4	0.5	6.2	6.4	
Average rank	8.18	4.63	8.06	10.80	8.05	9.59	4.77	3.33	9.41	4.35	11.35	4.75	14.50	11.58	6.65	
Probability of being in top 5 (%)	11.4	68.6	16.3	6.7	26.8	16.0	64.1	82.5	18.7	69.3	2.6	69.4	0.0	8.6	39.1	

Abbreviations: Vd, bortezomib + dexamethasone; XVd, selinexor + bortezomib + dexamethasone; BOR, bortezomib; Rd, lenalidomide + dexamethasone; KRd, carfilzomib + lenalidomide + dexamethasone; ERd, elotuzumab + lenalidomide + dexamethasone; IRd, ixazomib + lenalidomide + dexamethasone; EVd, elotuzumab + bortezomib + dexamethasone; VCyd, bortezomib + cyclophosphamide + dexamethasone; BEV+BOR, bevacizumab + bortezomib; SIL+BOR, siltuximab + bortezomib; Kd, carfilzomib + dexamethasone; DEX, dexamethasone; Td, thalidomide + dexamethasone; FVd, panobinostat + bortezomib + dexamethasone.

Table S5. 2L ORR Ranking Probability Results

Probability of Rank (%)	Treatment														
	Vd	XVd	BOR	Rd	KRd	DRd	IRd	RCyd	DVd	EVd	VCyd	BEV+ BOR	SIL+ BOR	DKd	Kd
Rank 1	0.0	0.7	0.0	0.0	0.6	2.9	0.0	1.7	13.7	0.0	0.0	0.0	0.0	77.5	0.0
Rank 2	0.0	6.0	0.0	0.0	3.0	8.1	0.0	5.8	42.7	0.1	0.0	0.0	0.0	15.0	4.8
Rank 3	0.0	12.7	0.0	0.0	5.6	9.7	0.0	8.5	17.5	0.4	0.0	0.0	0.0	4.3	16.5
Rank 4	0.0	14.5	0.0	0.0	6.9	8.6	0.1	8.6	11.0	1.0	0.1	0.0	0.0	1.9	21.1
Rank 5	0.0	16.3	0.0	0.0	7.7	8.9	0.2	8.9	6.5	2.3	0.5	0.0	0.0	0.8	20.9
Rank 6	0.2	15.4	0.0	0.1	9.5	10.0	0.3	10.1	4.1	5.1	0.9	0.0	0.0	0.3	16.6
Rank 7	1.2	13.9	0.0	0.2	11.7	10.8	0.7	11.6	2.4	8.2	1.9	0.0	0.0	0.2	11.1
Rank 8	4.8	9.9	0.0	0.5	12.8	11.2	1.8	11.3	1.3	13.7	4.9	0.1	0.0	0.1	5.7
Rank 9	12.9	6.3	0.0	1.3	13.1	9.6	3.0	10.9	0.6	15.5	7.1	0.1	0.0	0.0	2.5
Rank 10	23.4	2.8	0.0	2.5	9.8	7.1	5.3	7.6	0.2	17.6	11.3	0.3	0.1	0.0	0.6
Average rank	10.72	5.62	17.78	13.80	7.74	6.63	13.15	7.07	2.88	9.66	11.98	16.16	15.97	1.36	5.01
Probability of being in top 5 (%)	0.0	50.1	0.0	0.0	23.7	38.2	0.2	33.4	91.3	3.8	0.6	0.0	0.0	99.4	63.4

Abbreviations: Vd, bortezomib + dexamethasone; XVd, selinexor + bortezomib + dexamethasone; BOR, bortezomib; Rd, lenalidomide + dexamethasone; KRd, carfilzomib + lenalidomide + dexamethasone; DRd, daratumumab + lenalidomide + dexamethasone; IRd, ixazomib + lenalidomide + dexamethasone; RCyd, lenalidomide + cyclophosphamide + dexamethasone; DVd, daratumumab + bortezomib + dexamethasone; EVd, elotuzumab + bortezomib + dexamethasone; VCyd, bortezomib + cyclophosphamide + dexamethasone; BEV+BOR, bevacizumab + bortezomib; SIL+BOR, siltuximab + bortezomib; DKd, daratumumab + carfilzomib + dexamethasone; Kd, carfilzomib + dexamethasone.

Table S6. 3L+ PFS Ranking Probability Results

Probability of Rank (%)	Treatment														
	Vd	XVd	BOR	Rd	KRd	ERd	DRd	IRd	DVd	EVd	PVd	VOR+ BOR	DKd	Kd	DEX
Rank 1	0.0	0.1	0.0	0.0	0.0	0.0	33.5	1.2	3.5	1.3	0.1	0.0	48.3	0.0	0.0
Rank 2	0.0	0.4	0.0	0.0	0.4	0.8	22.0	6.7	12.2	3.1	0.9	0.0	24.0	1.2	0.0
Rank 3	0.0	1.2	0.0	0.0	1.4	2.5	12.5	9.1	17.8	4.3	3.0	0.0	11.6	4.3	0.0
Rank 4	0.0	2.3	0.0	0.0	2.6	4.3	8.1	8.9	16.7	4.9	6.2	0.0	6.0	8.7	0.0
Rank 5	0.0	3.5	0.0	0.0	3.9	5.4	5.6	8.2	13.0	5.2	9.4	0.0	3.6	12.2	0.0
Rank 6	0.0	5.0	0.0	0.1	4.7	6.0	4.5	7.4	9.7	5.6	11.8	0.0	2.3	13.9	0.0
Rank 7	0.0	7.1	0.0	0.3	5.4	6.3	4.1	7.2	7.6	6.2	13.0	0.0	1.6	13.3	0.0
Rank 8	0.2	9.8	0.0	0.7	5.9	6.9	3.9	7.7	5.9	7.4	12.2	0.0	1.0	11.3	0.0
Rank 9	1.4	10.7	0.0	1.1	7.0	8.0	3.1	8.8	4.5	7.7	10.2	0.0	0.7	9.1	0.0
Rank 10	4.2	9.3	0.0	1.4	8.6	9.9	1.5	9.4	3.1	6.8	8.4	0.0	0.4	7.4	0.0
Average rank	15.23	10.74	20.87	15.97	11.03	10.09	3.20	7.71	5.17	10.38	8.32	19.82	2.24	7.66	23.95
Probability of being in top 5 (%)	0.0	7.6	0.0	0.0	8.2	13.2	81.6	34.1	63.2	18.7	19.6	0.0	93.4	26.4	0.0

Abbreviations: Vd, bortezomib + dexamethasone; XVd, selinexor + bortezomib + dexamethasone; BOR, bortezomib; Rd, lenalidomide + dexamethasone; KRd, carfilzomib + lenalidomide + dexamethasone; ERd, elotuzumab + lenalidomide + dexamethasone; DRd, daratumumab + lenalidomide + dexamethasone; IRd, ixazomib + lenalidomide + dexamethasone; DVd, daratumumab + bortezomib + dexamethasone; EVd, elotuzumab + bortezomib + dexamethasone; PVd, pomalidomide + bortezomib + dexamethasone; VOR+BOR, vorinostat + bortezomib; BEV+BOR, bevacizumab + bortezomib; DKd, daratumumab + carfilzomib + dexamethasone; Kd, carfilzomib + dexamethasone; DEX, dexamethasone.

Table S7. 3L+ OS Ranking Probability Results

Probability of Rank (%)	Treatment														
	Vd	XVd	BOR	Rd	KRd	ERd	IRd	DVd	PVd	VOR+BOR	DKd	Kd	DEX	FVd	ISA+Pd
Rank 1	0.0	0.1	0.0	0.0	0.1	1.3	39.1	52.0	0.0	0.0	4.3	0.0	0.0	0.0	0.2
Rank 2	0.0	0.9	0.0	0.0	1.5	10.2	33.7	24.7	0.1	0.3	18.8	0.5	0.0	0.1	1.4
Rank 3	0.0	2.5	0.0	0.0	6.8	21.3	13.7	9.3	0.4	1.3	22.9	5.5	0.0	0.4	4.0
Rank 4	0.1	4.1	0.0	0.6	14.1	19.7	5.6	4.8	1.3	2.9	13.8	12.4	0.0	1.4	6.7
Rank 5	0.5	5.1	0.2	3.3	16.3	14.1	2.9	3.0	2.9	4.7	10.1	12.6	0.0	3.2	8.8
Rank 6	1.7	5.6	0.5	7.2	14.1	9.3	1.6	2.0	4.3	6.5	7.9	11.9	0.0	4.9	9.9
Rank 7	3.9	5.8	1.3	10.4	10.6	6.2	1.0	1.4	5.4	8.0	6.1	10.9	0.0	6.0	9.5
Rank 8	5.8	6.1	2.7	10.6	7.6	4.3	0.7	0.8	6.4	9.1	4.7	9.9	0.0	7.0	8.5
Rank 9	7.1	6.2	4.7	9.5	5.7	3.3	0.6	0.6	7.2	9.2	3.0	8.7	0.0	7.6	7.0
Rank 10	8.1	6.0	6.9	8.1	4.9	3.0	0.4	0.4	7.5	8.9	2.2	6.8	0.0	7.9	6.1
Average rank	13.02	11.98	13.64	11.05	7.20	5.22	2.25	2.13	12.53	10.67	4.75	7.74	19.99	12.10	9.47
Probability of being in top 5 (%)	0.5	12.8	0.2	3.9	38.8	66.4	95.0	93.9	4.7	9.2	69.9	31.1	0.0	5.1	21.1

Abbreviations: Vd, bortezomib + dexamethasone; XVd, selinexor + bortezomib + dexamethasone; BOR, bortezomib; Rd, lenalidomide + dexamethasone; KRd, carfilzomib + lenalidomide + dexamethasone; ERd, elotuzumab + lenalidomide + dexamethasone; IRd, ixazomib + lenalidomide + dexamethasone; DVd, daratumumab + bortezomib + dexamethasone; PVd, pomalidomide + bortezomib + dexamethasone; VOR+BOR, vorinostat + bortezomib; DKd, daratumumab + carfilzomib + dexamethasone; Kd, carfilzomib + dexamethasone; DEX, dexamethasone; FVd, panobinostat + bortezomib + dexamethasone; ISA+Pd, isatuximab + pomalidomide + dexamethasone.

Table S8. 3L+ ORR Ranking Probability Results

Probability of Rank (%)	Treatment														
	Vd	XVd	BOR	Rd	KRd	ERd	DRd	IRd	DVd	PVd	VOR+BOR	DKd	Kd	DEX	FVd
Rank 1	0.0	0.2	0.0	0.0	0.3	0.0	18.9	0.0	5.5	67.1	0.0	4.0	0.0	0.0	2.1
Rank 2	0.0	2.2	0.0	0.0	1.7	0.0	16.1	0.0	20.6	25.1	0.0	14.0	0.1	0.0	9.8
Rank 3	0.0	5.3	0.0	0.0	4.1	0.0	12.0	0.0	21.8	6.0	0.0	17.3	1.0	0.0	14.6
Rank 4	0.0	8.5	0.0	0.0	5.4	0.1	9.6	0.2	17.5	1.4	0.0	16.4	3.9	0.0	15.9
Rank 5	0.0	11.7	0.0	0.0	6.5	0.2	8.1	0.4	12.7	0.3	0.0	14.2	9.5	0.0	14.9
Rank 6	0.0	13.9	0.0	0.0	7.7	0.3	7.3	0.6	8.7	0.1	0.0	11.4	16.9	0.0	12.6
Rank 7	0.1	15.7	0.0	0.0	9.0	0.6	6.9	1.0	5.7	0.0	0.0	8.5	21.9	0.0	10.5
Rank 8	2.8	15.1	0.0	0.0	11.6	1.1	8.1	1.6	3.6	0.0	0.0	5.8	20.0	0.0	8.0
Rank 9	10.8	11.2	0.0	0.0	16.4	2.0	5.0	2.7	2.0	0.0	0.0	3.6	12.8	0.0	5.2
Rank 10	19.7	6.7	0.0	0.0	13.1	4.3	3.6	5.1	1.0	0.0	0.0	2.0	6.8	0.0	2.9
Average rank	13.02	11.98	13.64	11.05	7.20	5.22	2.25	2.13	12.53	10.67	4.75	7.74	19.99	12.10	9.47
Probability of being in top 5 (%)	0.5	12.8	0.2	3.9	38.8	66.4	95.0	93.9	4.7	9.2	69.9	31.1	0.0	5.1	21.1

Abbreviations: Vd, bortezomib + dexamethasone; XVd, selinexor + bortezomib + dexamethasone; BOR, bortezomib; Rd, lenalidomide + dexamethasone; KRd, carfilzomib + lenalidomide + dexamethasone; ERd, elotuzumab + lenalidomide + dexamethasone; DRd, daratumumab + lenalidomide + dexamethasone; IRd, ixazomib + lenalidomide + dexamethasone; DVd, daratumumab + bortezomib + dexamethasone; PVd, pomalidomide + bortezomib + dexamethasone; VOR+BOR, vorinostat + bortezomib; DKd, daratumumab + carfilzomib + dexamethasone; Kd, carfilzomib + dexamethasone; DEX, dexamethasone; FVd, panobinostat + bortezomib + dexamethasone.